Total Valuation
Bioxytran has a market cap or net worth of $2.44M. The enterprise value is $4.21M.
Market Cap$2.44M
Enterprise Value$4.21M
Share Statistics
Bioxytran has 114,695,220 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding114,695,220
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Bioxytran’s return on equity (ROE) is 0.82 and return on invested capital (ROIC) is 138.29%.
Return on Equity (ROE)0.82
Return on Assets (ROA)-3.22
Return on Invested Capital (ROIC)138.29%
Return on Capital Employed (ROCE)0.72
Revenue Per Employee0.00
Profits Per Employee-1.06M
Employee Count2
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Bioxytran is ―. Bioxytran’s PEG ratio is -0.09.
PE Ratio―
PS Ratio0.00
PB Ratio-2.69
Price to Fair Value-2.69
Price to FCF-13.22
Price to Operating Cash Flow-2.81
PEG Ratio-0.09
Income Statement
In the last 12 months, Bioxytran had revenue of 0.00 and earned -2.12M in profits. Earnings per share was -0.02.
Revenue0.00
Gross Profit-11.54K
Operating Income-1.85M
Pretax Income-2.12M
Net Income-2.12M
EBITDA-1.84M
Earnings Per Share (EPS)-0.02
Cash Flow
In the last 12 months, operating cash flow was -866.83K and capital expenditures 0.00, giving a free cash flow of -866.83K billion.
Operating Cash Flow-866.83K
Free Cash Flow-866.83K
Free Cash Flow per Share>-0.01
Dividends & Yields
Bioxytran pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta-1.23
52-Week Price Change-69.74%
50-Day Moving Average0.02
200-Day Moving Average0.04
Relative Strength Index (RSI)46.62
Average Volume (3m)219.43K
Important Dates
Bioxytran upcoming earnings date is ―, ―.
Last Earnings Date―
Next Earnings Date―
Ex-Dividend Date―
Financial Position
Bioxytran as a current ratio of 0.16, with Debt / Equity ratio of -17.30%
Current Ratio0.16
Quick Ratio0.16
Debt to Market Cap0.18
Net Debt to EBITDA-0.40
Interest Coverage Ratio-9.96
Taxes
In the past 12 months, Bioxytran has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Bioxytran EV to EBITDA ratio is -4.18, with an EV/FCF ratio of -14.63.
EV to Sales0.00
EV to EBITDA-4.18
EV to Free Cash Flow-14.63
EV to Operating Cash Flow-14.63
Balance Sheet
Bioxytran has $177.38K in cash and marketable securities with $855.00K in debt, giving a net cash position of -$677.62K billion.
Cash & Marketable Securities$177.38K
Total Debt$855.00K
Net Cash-$677.62K
Net Cash Per Share>-$0.01
Tangible Book Value Per Share-$0.03
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Bioxytran is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast―
EPS Growth Forecast-35.29%